

Clinical Policy: Cardiac Biomarker Testing

Reference Number: LA.CP.MP.156

Date of Last Revision: 10/22

Coding Implications
Revision Log

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

The release of cardiac biomarkers is among the cascade of events that occur during acute coronary syndromes and cardiac ischemia.¹ This policy discusses the **medical necessity** requirements for testing of these cardiac biomarkers.

Policy/Criteria

- I. It is the policy of Louisiana Healthcare Connections that troponin I or T testing is **medically necessary** and the appropriate cardiac biomarker for evaluating for suspected acute myocardial infarctions (AMI) or myocardial injury due to other mechanisms.
- II. It is the policy of Louisiana Healthcare Connections that creatine kinase myocardial isoenzyme (CK-MB) and myoglobin testing are **not medically necessary** in the evaluation for suspected AMI because troponin is the recommended biomarker due to its superior sensitivity and accuracy.

Background

Detection of specific cardiac biomarkers in blood serum is a useful clinical indication of acute myocardial infarctions (AMI), myocarditis, or heart failure.² Cardiac troponins I and T have become the preferred biomarkers used for diagnoses of acute coronary syndromes due to their high specificity and sensitivity and because these subunits are expressed in the myocardium. Furthermore, troponin levels are also elevated for acute and chronic decompensated heart failure in instances of myocyte injury and/or necrosis.⁷⁻⁸

Other cardiac peptides that were previously assessed for AMI include creatine kinase myocardial isoenzyme (CK-MB) and myoglobin. However, recent evidence suggests that the sensitivity and specificity of these biomarkers are inferior compared to the troponins, suggesting that troponins are a more accurate biomarker of myocardial injury.^{1-2,7} According to the 2014 American College of Cardiologists/American Heart Association (ACC/AHA) clinical practice guidelines, CK-MB and myoglobin are no longer necessary for acute coronary syndrome diagnosis as a result of the advent of troponin assays.¹ CK-MB detection is comparatively less sensitive and less specific.¹⁻⁷ A 2010 retrospective cohort study was performed in an emergency department over a 12 month period examining patients who had troponin testing.⁹ The study included 11,092 visits where at least one troponin test was ordered, and 97.9% of these patients also had a CK-MB ordered.⁹ The authors concluded that CK-MB testing can be omitted during the initial screening of AMIs since the study showed a 0% rate of positive CK-MB index with negative troponin.⁹ Eggers et al, evaluated the role of myoglobin with troponin I to detect AMI in a sample of 197 patients and determined that neither myoglobin nor CK-MB added clinical diagnostic value.¹⁰ Aviles et al analyzed AMI amongst patients with elevated cardiac troponins in a prospective cohort and noted that at least 20% of patients had normal CK-MB levels, thereby further questioning the validity of CK-MB as a valuable cardiac biomarker.¹¹ Of note,

Singh *et al.* measured CK-MB testing from 2007 to 2013 and found a dramatic decrease from 12,057 tests in 2007 to 36 tests in 2013.⁵

Coding Implications

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2020, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only and may not support medical necessity. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

Table 1: CPT codes not medically necessary when billed with CPT 84484 Troponin

CPT Codes	Description
82553	Creatine kinase (CK), (CPK); MB fraction only
83874	Myoglobin

Reviews, Revisions, and Approvals	Revision Date	Approval Date
Converted corporate to local policy.	08/15/2020	
Added “or myocardial injury due to other mechanisms” in addition to acute myocardial infarction for approval in criteria I. References reviewed and updated. Coding reviewed. Changed “review date” in the header to “date of last revision” and “date” in the revision log header to “revision date.” Added “and may not support medical necessity” to coding implications. Reviewed by specialist.	2/22	4/14/22
Annual review. Background updated with no impact on criteria.	10/22	1/14/23

References

1. Jaffe AS, Morrow DA. Biomarkers of myocardial injury other than troponin. UpToDate. www.uptodate.com. Published February 15, 2021. Accessed August 19, 2022.
2. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in *Circulation*. 2014 Dec 23;130(25):e433-4. Dosage error in article text]. *Circulation*. 2014;130(25):e344-e426. doi:10.1161/CIR.0000000000000134
3. Neumann JT, Sørensen NA, Schwemer T, et al. Diagnosis of Myocardial Infarction Using a High-Sensitivity Troponin I 1-Hour Algorithm. *JAMA Cardiol* 2016;1(4): 397-404. doi:10.1001/jamacardio.2016.0695

4. Reeder GS, Kennedy HL. Diagnosis of acute myocardial infarction. UpToDate. www.uptodate.com. Published February 25, 2021. Accessed August 23, 2022.
5. deFilippi C, Henrich WL. Cardiac troponins in patients with renal failure. UpToDate. www.uptodate.com. Published June 9, 2022. Accessed August 23, 2022.
6. Jaffe AS, Morrow DA. Troponin testing: Clinical use. UpToDate. www.uptodate.com. Published January 14, 2021. Accessed September 15, 2021.
7. Local coverage determination: Troponin (L33974). Centers for Medicare and Medicaid Services Web site. <http://www.cms.hhs.gov/mcd/search.asp>. Published October 1, 2015 (revised October 1, 2019.) Accessed September 15, 2021.
8. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *Circulation*. 2017;136(6):e137 to e161. doi:10.1161/CIR.0000000000000509
9. Volz KA, McGillicuddy DC, Horowitz GL, Sanchez LD. Creatine kinase-MB does not add additional benefit to a negative troponin in the evaluation of chest pain. *Am J Emerg Med* 2012;30(1):188 to 190. doi:10.1016/j.ajem.2010.10.016
10. Eggers KM, Oldgren J, Nordenskjöld A, Lindahl B. Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. *Am Heart J*. 2004;148(4):574 to 581. doi:10.1016/j.ahj.2004.04.030
11. Aviles RJ, Wright RS, Aviles JM, et al. Long-term prognosis of patients with clinical unstable angina pectoris without elevation of creatine kinase but with elevation of cardiac troponin i levels. *Am J Cardiol*. 2002;90(8):875 to 878. doi:10.1016/s0002-9149(02)02712-1
12. Singh G, Baweja PS. Creatine kinase-MB: the journey to obsolescence. *Am J Clin Pathol* 2014;141(3):415 to 419. doi:10.1309/AJCPBIK3G4BWEJKO

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy,

CLINICAL POLICY

Cardiac Biomarker Testing for Acute Myocardial Infarction



contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

©2020 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.